REDX-05358

CAS No. 1884226-20-3

REDX-05358( REDX 05358 | REDX05358 )

Catalog No. M12942 CAS No. 1884226-20-3

REDX-05358 is a novel potent, highly selective, orally bioavailable pan RAF inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    REDX-05358
  • Note
    Research use only, not for human use.
  • Brief Description
    REDX-05358 is a novel potent, highly selective, orally bioavailable pan RAF inhibitor.
  • Description
    REDX-05358 is a novel potent, highly selective, orally bioavailable pan RAF inhibitor with IC50 of 0.1, 0.68, 0.171, and 0.076 nM for ARAF, BRAF, BRAF (V600E), and CRAF, respectively; denmonstrates high selectivity profile against a panel of 468 kinases, exhibits negligible paradoxical activation due to inhibition of both RAF monomers and dimers; not only inhibits MAPK signalling in BRAF V600E mutant tumor cells, but also in those harbouring NRAS and KRAS mutations; exhibits in vivo efficacy in BRAF V600E CRC xenograft model.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    REDX 05358 | REDX05358
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1884226-20-3
  • Formula Weight
    472.929
  • Molecular Formula
    C26H21ClN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : < 0.1 mg/mL (insoluble))
  • SMILES
    O=C(CC1)NC2=C1C(OC3=CC(CC(C4=NC=C(C5=CC=CC=C5Cl)N4)CO6)=C6C=C3)=CC=N2
  • Chemical Name
    5-[[3-[5-(2-Chlorophenyl)-1H-imidazol-2-yl]chroman-6-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Helen Mason, et al. AACR, Abstract 5160.
molnova catalog
related products
  • GDC-0349

    GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.

  • I-49 free base

    I-49 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.

  • Dabrafenib Mesylate

    Dabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).